State public health agencies mandate blood draws from virtually all 4 million neonates born in the United States each year. The samples are tested for a host of inborn conditions that can be harmful, even fatal, if not treated soon after birth. Included are metabolic disorders, like galactosemia, and conditions such as congenital hypothyroidism.
Nearly 12 000 affected infants are identified annually and need swift treatment. But there are delays in getting test results back promptly. Reasons for delays range from failure to perform early screening following out-of-hospital births and the remoteness of rural hospitals to limited courier availability to convey blood specimens to labs and insufficient lab hours.
Lyon J. Concerns Over Newborn Screening. JAMA. 2017;317(6):576. doi:10.1001/jama.2017.0080
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: